Drugs / Ulviprubart
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04659031 | May 2021 → Jan 2025 | inclusion body myositis | Abcuro, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05532722 | Sep 2022 → Aug 2025 | T-cell large granular lymphocyte leukemia | Abcuro, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06450886 | Oct 2024 → Jan 2029 expected | inclusion body myositis | Abcuro, Inc. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05721573 Comparator | Feb 2023 → Nov 2025 | inclusion body myositis | Abcuro, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
All press releases naming this drug 13 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulviprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06450886 ↗ |
| Known as | ABC008 | “Ulviprubart (ABC008)” NCT06450886 ↗ |
| Action | Deplete | “evaluate the recovery of the depletion of killer cell lectin-like receptor G1 (KLRG1)+ cells after the end of treatment with ABC008” NCT05721573 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650433 ↗ |
| Route | Subcutaneous | “Given subcutaneous injection” NCT05532722 ↗ |